LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

LLY

733.18

-2.5%↓

JNJ

153.97

-1.02%↓

UNH

380.38

-1.39%↓

ABBV

184.25

-0.64%↓

ABT

133.26

-0.42%↓

Search

Kura Oncology Inc

Closed

SectorHealthcare

5.76 -4.32

Overview

Share price change

24h

Current

Min

5.76

Max

5.87

Key metrics

By Trading Economics

Income

-38M

-57M

Sales

-40M

14M

EPS

-0.66

Profit margin

-407.067

Employees

192

EBITDA

-48M

-65M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+292.36% upside

Dividends

By Dow Jones

Next Earnings

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

56M

582M

Previous open

10.08

Previous close

5.76

News Sentiment

By Acuity

50%

50%

194 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Kura Oncology Inc Chart

Past performance is not a reliable indicator of future results.

Related News

9 May 2025, 17:03 UTC

Earnings
Major Market Movers

Anika Therapeutics Shares Fall After Slump in 1Q Pain-Treatment Sales in U.S.

10 May 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9 May 2025, 23:51 UTC

Acquisitions, Mergers, Takeovers

Oil at $50? The High Cost of Cheap Crude. -- Barrons.com

9 May 2025, 22:06 UTC

Market Talk

Arm Holdings Remains a Strong Growth Story -- Market Talk

9 May 2025, 21:37 UTC

Top News

U.S. Sets August Deadline for Debt Ceiling -- WSJ

9 May 2025, 21:10 UTC

Top News

The Score: Disney, Berkshire Hathaway, Ford and More Stocks That Defined the Week -- WSJ

9 May 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9 May 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

9 May 2025, 20:42 UTC

Top News

Stocks Get a Break From Trade Chaos -- WSJ

9 May 2025, 20:21 UTC

Top News

Trump Floats Lowering China Tariffs to 80%, Says Many Trade Deals to Come -- WSJ

9 May 2025, 19:23 UTC

Market Talk

Oil Snaps Losing Streak on Optimism Over Trade Talks -- Market Talk

9 May 2025, 19:01 UTC

Market Talk

U.S. Natural Gas Posts Second Weekly Gain -- Market Talk

9 May 2025, 18:56 UTC

Earnings

Dr Reddy's Laboratories 4Q EPS INR19.11 >RDY

9 May 2025, 18:56 UTC

Earnings

Dr Reddy's Laboratories 4Q Rev INR85.06B >RDY

9 May 2025, 18:52 UTC

Market Talk

Gold Resumes Upward Momentum -- Market Talk

9 May 2025, 18:12 UTC

Market Talk

Lower Diesel Prices Provide Some Relief for Truckers -- Market Talk

9 May 2025, 18:02 UTC

Top News

Trump Floats 80% China Tariff, Says Many Trade Deals 'In the Hopper' -- WSJ

9 May 2025, 17:30 UTC

Market Talk

U.S. Oil Rig Count Falls by 5 to 474 -- Market Talk

9 May 2025, 17:21 UTC

Earnings

Trade Desk Stock Is Surging on Earnings. There Are 'Significant Opportunities.' -- Barrons.com

9 May 2025, 17:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 May 2025, 17:14 UTC

Market Talk

Canada's Softening Labor Data May Not Clinch Another Rate Cut -- Market Talk

9 May 2025, 17:12 UTC

Market Talk

Mexican Industrial Production Seen Mixed in March -- Market Talk

9 May 2025, 16:51 UTC

Earnings
Acquisitions, Mergers, Takeovers

Affirm's Weak Guidance Hits the Stock. Why This Analyst Upgraded the Shares. -- Barrons.com

9 May 2025, 16:50 UTC

Earnings

Turkcell Iletisim Hizmetleri 1Q Net TRY3.08B >TKC

9 May 2025, 16:49 UTC

Earnings

Turkcell Iletisim Hizmetleri 1Q Rev TRY47.96B >TKC

9 May 2025, 16:49 UTC

Market Talk

Weak Canadian Employment Trend Continues, Seen Leaving Door Open to Rate Cut -- Market Talk

9 May 2025, 16:41 UTC

Earnings

Pinterest Shows Strength in Uncertain Advertising Market -- Barrons.com

9 May 2025, 16:30 UTC

Top News

China Sends Xi's Security Czar to Trade Talks With U.S. -- WSJ

9 May 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9 May 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

Peer Comparison

Price change

Kura Oncology Inc Forecast

Price Target

By TipRanks

292.36% upside

12 Months Forecast

Average 22.6 USD  292.36%

High 40 USD

Low 10 USD

Based on 13 Wall Street analysts offering 12 month price targets forKura Oncology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

10

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

5.575 / 6.6Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

194 / 382 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.